



**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Srinivasan Dasarathy, MD**

Committee: **Pharmacy Compounding Advisory Committee (PCAC)**

Meeting Date: **June 8, 2022**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda items described below, I may be considered for participation in the advisory committee meeting.

On June 8, 2022, the committee will discuss ammonium tetrathiomolybdate as a bulk drug substance nominated for inclusion on the 503A Bulk List. The nominators of the substance or another interested party will be invited to make a short presentation supporting the nomination. Ammonium tetrathiomolybdate uses are evaluated for Wilson disease, use as copper (Cu) chelation therapy for the treatment of breast cancer, kidney cancer, prostate cancer, colorectal cancer, esophageal cancer, and malignant pleural mesothelioma.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
Stocks/investments	<div style="background-color: #cccccc; width: 100%; height: 100%; display: flex; align-items: center; justify-content: center;"> <span style="font-size: small; margin-right: 5px;">PPI</span> </div> <div style="background-color: #cccccc; width: 100%; height: 100%; display: flex; align-items: center; justify-content: center;"> <span style="font-size: small; margin-right: 5px;">PPI</span> </div> funds healthcare sector	Aggregate value of \$100,00-150,000
<b>II. Other Imputed Interests</b>		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_  
/s/  
Signature

\_\_\_\_\_  
5/17/22  
Date